Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools

    < Back to search results

    Print Download

    EudraCT Number:2012-003176-39
    Sponsor's Protocol Code Number:205MS303
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2013-01-11
    Trial results View results
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2012-003176-39
    A.3Full title of the trial
    A Multicenter, Open-Label, Extension Study to Evaluate the Long Term
    Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed
    Study 205MS301.
    Studio di estensione multicentrico, in aperto, per valutare la sicurezza e la efficacia a lungo termine di BIIB019, Daclizumab High Yield Process (DAC HYP), in monoterapia in soggetti con sclerosi multipla che hanno completato lo studio 205MS301.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Daclizumab HYP Extension Study for Subjects with Multiple Sclerosis Who
    Have Completed 203MS301.
    Studio di estensione con Daclizumab HYP in soggetti con sclerosi multipla che hanno completato la sperimentazione 203MS301.
    A.3.2Name or abbreviated title of the trial where available
    A.4.1Sponsor's protocol code number205MS303
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBIOGEN IDEC RESEARCH LTD
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBiogen Idec Research Limited
    B.4.2CountryUnited Kingdom
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationBiogen Idec Research Limited
    B.5.2Functional name of contact pointEXTEND Clinical Trials Team
    B.5.3 Address:
    B.5.3.1Street AddressInnovation House, 70 Norden Road
    B.5.3.2Town/ cityMaidenhead, Berkshire
    B.5.3.3Post codeSL64AY
    B.5.3.4CountryUnited Kingdom
    B.5.4Telephone number-
    B.5.5Fax number-
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameDaclizumab HYP
    D.3.2Product code BIIB019
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDACLIZUMAB
    D.3.9.1CAS number 152923-56-3
    D.3.9.2Current sponsor codeBIIB019
    D.3.9.3Other descriptive nameDaclizumab HYP (DAC HYP
    D.3.9.4EV Substance CodeSUB06885MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number150
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D. cell therapy medicinal product No
    D. therapy medical product No
    D. Engineered Product No
    D. ATIMP (i.e. one involving a medical device) No
    D. on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Relapsing-remitting Multiple Sclerosis
    Sclerosi multipla recidivante-remittente
    E.1.1.1Medical condition in easily understood language
    Multiple Sclerosis
    Sclerosi multipla
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.1
    E.1.2Level PT
    E.1.2Classification code 10063399
    E.1.2Term Relapsing-remitting multiple sclerosis
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of the study is to assess the safety and tolerability of long-term treatment with DAC HYP monotherapy in subjects who completed Study 205MS301.
    L’obiettivo primario dello studio è quello di valutare la sicurezza e la tollerabilità del trattamento a lungo termine con DAC HYP in monoterapia in soggetti che hanno completato lo studio 205MS301.
    E.2.2Secondary objectives of the trial
    • To assess the long-term immunogenicity of DAC HYP administered by PFS • To describe MS-related outcomes, including MS relapse, disability progression, MS lesion formation, and patient-reported impact of MS, following long-term treatment with DAC HYP • To assess the safety, tolerability, and efficacy of switching to DAC HYP in subjects previously on long-term treatment with interferon β 1a in Study 205MS301 • To evaluate PD parameters that may be associated with treatment response.
    • valutare l’immunogenicità a lungo termine di DAC HYP somministrato mediante siringa preriempita (Prefilled Syringe, PFS); • descrivere gli esiti correlati alla SM, comprese recidive di SM, progressione della disabilità, formazione di lesioni da SM e impatto della SM riferito dal paziente a seguito del trattamento a lungo termine con DAC HYP; • valutare la sicurezza, la tollerabilità e l’efficacia del passaggio a DAC HYP nei soggetti precedentemente sotto trattamento a lungo termine con interferone β-1a nello studio 205MS301; • valutare i parametri di farmacodinamica (PD) che possono essere associati alla risposta al trattamento.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations. 2. Must be a subject currently participating in Study 205MS301 who has completed either the Week 144 Visit or the End of Study Visit (Week 96). Note: Subjects who are not able to enroll into 205MS303 at the time of their Week 144/End of Study Visit may be eligible to enroll into 205MS303 at a later time if they are still participating in the 6-month follow-up period of 205MS301 at the time of expected rollover into 205MS303. 3. Women of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 4 months after their last dose of study treatment.
    1. capacità di comprendere lo scopo e i rischi associati allo studio, fornire un consenso informato datato e firmato e l’autorizzazione all’utilizzo di informazioni sanitarie protette (Protected Health Information, PHI) in conformità alle normative nazionali e locali riguardanti la privacy del soggetto; 2. soggetto attualmente partecipante allo studio 205MS301 che ha completato la Visita della Settimana 144 o la Visita di Fine Studio (Settimana 96). Nota: i soggetti che non possono essere arruolati nello studio 205MS303 al momento della loro Visita della Settimana 144/Visita di fine studio possono essere idonei all’arruolamento nello studio 205MS303 in un secondo momento, se stanno ancora partecipando al periodo di follow-up di 6 mesi previsto dallo studio 205MS301 al momento dell’atteso passaggio allo studio 205MS303; 3. le donne potenzialmente fertili devono utilizzare una contraccezione efficace durante lo studio ed essere disposte a continuare la contraccezione per 4 mesi dopo l’assunzione dell’ultima dose del trattamento in studio.
    E.4Principal exclusion criteria
    Medical History 1. Any subject who permanently discontinued study treatment in Study 205MS301 prior to the end of the study treatment period, or had an Early Termination visit in Study 205MS301. Note: Subjects for whom dosing was temporarily suspended in Study 205MS301 are not excluded from participation in this extension study if the criteria for resuming DAC HYP treatment under the Study 205MS301 protocol have been met at the time of enrollment into Study 205MS303. 2. Any significant change in the subject's medical history that would preclude administration of DAC HYP, including laboratory tests or a current clinically significant condition that, in the opinion of the Investigator, would have excluded the subject's participation in Study 205MS301. The Investigator must re review the subject's medical fitness for participation and consider any factors that would preclude treatment in Study 205MS303, including: • History of any significant cardiac, endocrine, hematological, hepatic, immunologic, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric, renal, neurological (other than MS), and/or other major disease (e.g., malignancy) that would preclude administration of DAC HYP. • Clinically significant laboratory abnormalities (hematology and blood chemistry) from the most recently available test in Study 205MS301, as determined by the Investigator. Laboratory findings mandating discontinuation of study treatment as defined in Protocol 205MS301 are exclusionary. 3. Any of the following abnormal blood tests within the 7 days prior to Day 1: • alanine aminotransferase/serum glutamate pyruvate transaminase (ALT/SGPT), aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT), or gamma-glutamyl-transferase (GGT) >3x the upper limit of normal (ULN) Note: Subjects ending 205MS301 on a treatment suspension may not enroll into 205MS303 until ALT/SGPT and AST/SGOT are minor or = 2x ULN. • total bilirubin >2x ULN (subjects with an established diagnosis of Gilbert's syndrome are excluded if total bilirubin is >2.5x ULN) Note: Subjects ending 205MS301 on a treatment suspension may not enroll into 205MS303 until total bilirubin minor or =1x ULN (subjects with an established diagnosis of Gilbert's syndrome may not enroll into 205MS303 until total bilirubin is minor or = 1.5x ULN). 4. Other medical reasons that, in the opinion of the Investigator and/or Biogen Idec, make the subject unsuitable for enrollment. Treatment History 5. Treatment with any prohibited concomitant medication during Study 205MS301. Note: Subjects who start an approved, open-label IFN β preparation after completion of dosing in Study 205MS301 are not excluded, but IFN β treatment must be discontinued before the first dose of DAC HYP in Study 205MS303 is given. Miscellaneous 6. Female subjects who are currently pregnant or breastfeeding, or considering becoming pregnant while in the study. 7. Previous participation in Study 205MS303. 8. History of drug or alcohol abuse (as defined by the Investigator) at any time after the start of Study 205MS301. 9. Unwillingness or inability to comply with the requirements of the protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's ability to comply with the protocol.
    Anamnesi 1. Qualsiasi soggetto che abbia interrotto il trattamento nello studio 205MS301 in modo permanente prima della fine del periodo di trattamento o che sia stato sottoposto alla Visita di interruzione anticipata nello studio 205MS301. Nota: i soggetti per i quali il dosaggio era stato temporaneamente sospeso nello studio 205MS301 non sono esclusi dalla partecipazione a questo studio di estensione se, al momento dell’arruolamento nello studio 205MS303, sono stati soddisfatti i criteri per riprendere il trattamento con DAC HYP secondo il protocollo dello studio 205MS301. 2. Qualsiasi cambiamento significativo nell’anamnesi del soggetto che possa precludere la somministrazione di DAC HYP, compresi test di laboratorio o una patologia clinicamente significativa in corso che, a giudizio dello sperimentatore, avrebbe escluso la partecipazione del soggetto nello studio 205MS301. Lo sperimentatore deve riesaminare l’idoneità medica del soggetto per la partecipazione e considerare qualsiasi fattore che precluda il trattamento nello studio 205MS303, tra cui: • Storia di una malattia significativa a livello cardiaco, endocrino, ematologico, epatico, immunologico, metabolico, urologico, polmonare, gastrointestinale, dermatologico, psichiatrico, renale, neurologico (diversa dalla SM) e/o altra malattia importante (ad es., neoplasia maligna) che precluderebbe la somministrazione di DAC HYP. • Anomalie di laboratorio clinicamente significative (ematologia ed ematochimica) emerse dall’analisi più recente disponibile nello studio 205MS301, determinate dallo sperimentatore. Esiti di laboratorio che obbligano a interrompere il trattamento in studio come definito nel Protocollo 205MS301 comporteranno l’esclusione. 3. Uno qualsiasi dei seguenti esami del sangue risultante anomalo entro 7 giorni dal Giorno 1: • Alanina aminotransferasi/glutammico piruvico transaminasi sierica (ALT/SGPT), aspartato aminotransferasi/glutammico ossalacetico transaminasi sierica (AST/SGOT) oppure gamma glutamil transferasi (GGT) &gt;3x rispetto al limite superiore al normale (ULN). Nota: i soggetti che hanno terminato lo studio 205MS301 durante una sospensione del trattamento non potranno arruolarsi nello studio 205MS303 finché i valori ALT/SGPT e AST/SGOT non saranno minore o =2x ULN. • Bilirubina totale &gt;2x ULN (i soggetti con una diagnosi conclamata di sindrome di Gilbert sono esclusi se la bilirubina totale è &gt;2,5x ULN). Nota: i soggetti che hanno terminato lo studio 205MS301 durante una sospensione del trattamento non potranno arruolarsi nello studio 205MS303 finché i valori della bilirubina totale non saranno minore o =1x ULN (i soggetti con una diagnosi conclamata di sindrome di Gilbert sono esclusi finché la bilirubina totale non è minore o = 1,5 xULN). 4. Motivazioni mediche di altro tipo che, a giudizio dello sperimentatore e/o di Biogen Idec, rendano il soggetto non idoneo all’arruolamento. Anamnesi di trattamento 5. Trattamento con qualsiasi farmaco concomitante proibito durante lo studio 205MS301. Nota: i soggetti che iniziano ad assumere una preparazione approvata e in aperto di IFN β dopo aver completato l’assunzione delle dosi dello studio 205MS301 non sono esclusi, ma il trattamento con IFN β deve essere interrotto prima della somministrazione della prima dose di DAC HYP nello studio 205MS303. Varie 6. Soggetti di sesso femminile attualmente in gravidanza o che stanno allattando al seno o che intendono iniziare una gravidanza durante lo studio. 7. Precedente partecipazione allo studio 205MS303. 8. Precedente abuso di alcol o droghe (secondo quanto definito dallo sperimentatore) in qualsiasi momento dopo l’inizio dello studio 205MS301. 9. Rifiuto o impossibilità di rispettare i requisiti del protocollo, compresa la presenza di qualsiasi patologia (fisica, mentale o sociale) che possa influire
    E.5 End points
    E.5.1Primary end point(s)
    Primary End Points include incidence of AEs including serious AEs (SAEs), discontinuation of DAC HYP due to AEs, and withdrawals due to AEs
    Incidenza di eventi avversi (AE) ed eventi avversi seri (SAE).
    E.5.1.1Timepoint(s) of evaluation of this end point
    As necessary
    Quando necessario.
    E.5.2Secondary end point(s)
    • Shifts in clinical laboratory assessments (hematology and blood chemistry) • Incidence of depression as assessed by the Beck Depression Inventory, Second Edition (BDI-II) • Incidence of anti-DAC binding antibodies (ADAbs) over time • Incidence of anti-DAC HYP neutralizing antibodies (NAbs) over time • Relapse outcomes: annualized relapse rate (ARR), and proportion of subjects who relapse • Sustained disability progression defined by at least a 1.0 point increase on the Expanded Disability Status Scale (EDSS) score from a baseline EDSS ≥1.0 that is sustained for 12 weeks, or at least a 1.5-point increase on the EDSS from a baseline EDSS <1.0 that is sustained for 12 weeks • Magnetic Resonance Imaging (MRI) outcomes: total number and volume of new or newly enlarging T2 hyperintense lesions, Gdenhancing lesions, T1 hypointense lesions, and brain atrophy on brain MRI (Note: The decision to collect and analyze brain atrophy data will be made after the analysis of Study 205MS301 is complete. Brain atrophy analysis may be omitted.) • Change in Multiple Sclerosis Functional Composite (MSFC) score • Change in EDSS score • Proportion of subjects who are free from disease activity. • Proportion of subjects with sustained improvement in disability as defined by the number of subjects with baseline EDSS of at least 2.0 who experience ≥1.0 decrease in EDSS that is sustained for 24 weeks. • Change in Multiple Sclerosis Impact Scale-29 (MSIS-29) physical and psychological scores • Change in quality of life as assessed by the European Quality of Life, 5 dimensions (EQ-5D and EQ VAS) • Change in direct HRU (hospitalizations, emergency room visits, and unscheduled neurologist visits) • Change in treatment satisfaction as assessed by the subject • Change in subject productivity as assessed by the HRPQ
    • Cambiamenti nelle valutazioni cliniche di laboratorio (ematologia ed ematochimica). • Incidenza di depressione come valutato dall’Inventario della depressione di Beck, seconda edizione (BDI-II). • Incidenza di anticorpi leganti anti-DAC HYP (ADAbs) nel tempo. • Incidenza di anticorpi neutralizzanti anti-DAC HYP (NAbs) nel tempo. • Esiti delle recidive: tasso annuale di recidive (Annualized Relapse Rate, ARR) e percentuale di soggetti che presentano recidive. • Progressione sostenuta della disabilità definita da almeno 1,0 punto di aumento sulla Scala espansa dello stato di disabilità (Expanded Disability Status Scale, EDSS) da un basale EDSS ≥1,0 sostenuto per 12 settimane, o da almeno un aumento di 1,5 punti sull’EDSS dal basale EDSS <1,0 che sia sostenuto per 12 settimane. • Esiti della risonanza magnetica per immagini (RMI): numero e volume totale di lesioni iperintense in T2 nuove o recentemente ingrandite, lesioni captanti gadolinio (Gd), lesioni ipointense in T1 e atrofia cerebrale emersa dalla RMI cerebrale (nota: la decisione di raccogliere e analizzare informazioni sull’atrofia cerebrale verrà presa dopo il completamento dell’analisi dello studio 205MS301. L’analisi dell’atrofia cerebrale può essere omessa). • Cambiamento del punteggio nella scala Multiple Sclerosis Functional Composite (MSFC). • Cambiamento del punteggio EDSS. • Percentuale di soggetti liberi da attività patologica. • Percentuale di soggetti con miglioramento sostenuto della disabilità come definito dal numero di soggetti con EDSS al basale di almeno 2,0 che hanno evidenziato una diminuzione di ≥1,0 dell’EDSS che è sostenuta per 24 settimane. • Cambiamento del punteggio fisico e psicologico nella Scala d’impatto della sclerosi multipla 29 (Multiple Sclerosis Impact Scale, MSIS-29). • Cambiamento nella di vita sulla base delle valutazioni secondo il Questionario europeo sulla qualità della vita in 5 dimensioni (European Quality of Life, 5 dimensions, (EQ-5D e EQVAS). • Cambiamento nell’utilizzo diretto delle risorse sanitarie (Health Resource Utilization, HRU, ospedalizzazione, visite al pronto soccorso e visite neurologiche non programmate). • Cambiamento nella soddisfazione del trattamento in base alle valutazioni del soggetto. • Cambiamento nella produttività del soggetto, in base alle valutazioni del Questionario sulla produttività legata allo stato di salute (Health Related Productivity Questionnaire, HRPQ).
    E.5.2.1Timepoint(s) of evaluation of this end point
    Throughout the course of the study
    Nel corso della sperimentazione.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E. trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Information not present in EudraCT
    E.8.2.2Placebo Information not present in EudraCT
    E.8.2.3Other Information not present in EudraCT
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned8
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA120
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Moldova, Republic of
    Russian Federation
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months41
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years0
    E.8.9.2In all countries concerned by the trial months42
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1Number of subjects for this age range: 0
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 1841
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state97
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 889
    F.4.2.2In the whole clinical trial 1841
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    As per protocol.
    Come da protocollo.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2013-03-14
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2013-01-14
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands